Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acadesine in Refractory MDS, CMML, and AML
NCT01813838Phase 2Terminated
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Jun 2013
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acadesine in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Started Jun 2013; status: terminated.
02
Drugs
acadesine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01813838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813838.